For the Inventor, By the Inventor

Enter assignee name

Mountain View, CA, United States of America

Chemocentryx, Inc.

USPTO Granted Patents = 220

% Expired Patents = 1.8

CIPO Patents = 8

EPO Patents = 69

Trademarks = 5

Forward Citations = 1,392

Loading Chart...

Loading Chart...

114 inventors (with patents filed for the assignee):

Penglie Zhang (109 out of 128 patents)

Sreenivas Punna (67 out of 67 patents)

Yibin Zeng (65 out of 69 patents)

4. Jay Patrick Powers (55 out of 126 patents)

5. Ju Yang (51 out of 55 patents)

6. Venkat Reddy Mali (50 out of 60 patents)

7. Rajinder Paul Singh (50 out of 379 patents)

8. Pingchen Fan (47 out of 63 patents)

9. Manmohan Reddy Leleti (41 out of 72 patents)

10. Christopher W Lange (41 out of 48 patents)

11. Hiroko Tanaka (41 out of 47 patents)

12. Thomas J Schall (41 out of 52 patents)

13. Viengkham Malathong (40 out of 52 patents)

14. Rebecca M Lui (39 out of 42 patents)

15. Antoni Krasinski (36 out of 37 patents)

Core Competencies:

CCR2 Antagonists

PD-L1 Inhibitors

C5aR Antagonists

CXCR2 Inhibitors

Immunomodulators

Triaryl Compounds

Inflammatory Bowel Disease

Focal Segmental Glomerulosclerosis

Combination Therapy

Heteroaryl Compounds

Tumor Treatment

Small Molecule Inhibitors

220 patents: Sort by Forward Citations

1. 12758558 - Methods of treating solid tumors with CCR2 antagonists (2026-10-13),

2. 12734166 - Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies (2026-09-15),

3. 12611409 - Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor (2026-04-28),

4. 12611404 - Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides (2026-04-28),

5. 12533354 - Triaryl compounds for treatment of PD-L1 diseases (2026-01-27),

6. 12497383 - Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases (2025-12-16),

7. 12350263 - Dosing and effect of C5a antagonist with ANCA-associated vasculitis (2025-07-08),

8. 12268675 - Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors (2025-04-08),

9. 12194032 - Method of treating focal segmental glomerulosclerosis (2025-01-14),

10. 12139475 - 2-oxindole compounds (2024-11-12),

11. 12054484 - Substituted tetrahydropyrans as CCR2 modulators (2024-08-06),

12. 12012403 - Aryl sulfonyl compounds as CCR6 inhibitors (2024-06-18),

13. 12011439 - Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors (2024-06-18),

14. 11986466 - Methods of treating solid tumors with CCR2 antagonists (2024-05-21),

15. 11951214 - Capsule formulations (2024-04-09),

Company Overview

Chemocentryx, Inc. is a biopharmaceutical company based in Mountain View, California, specializing in the development of innovative therapies targeting chemokine receptors. The company's core focus includes the modulation of CCR2, PD-L1, C5aR, and CXCR2, which are critical in various inflammatory and autoimmune conditions. Chemocentryx is dedicated to advancing treatments for diseases such as inflammatory bowel disease and focal segmental glomerulosclerosis through its proprietary immunomodulatory compounds.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

220 Patents

#17 in Mountain View, CA

#411 in California

#1,906 in US

#3,889 in the World

Mountain View, CA, United States of America

Chemocentryx, Inc.

Forward Citations = 1,392

114 inventors:

Penglie Zhang (109 out of 128 patents)

Sreenivas Punna (67 out of 67 patents)

Yibin Zeng (65 out of 69 patents)

4. Jay Patrick Powers (55 out of 126 patents)

5. Ju Yang (51 out of 55 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Chemocentryx, Inc.. Retrieved from https://idiyas.com/company/chemocentryx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…